Pfizer Pulls Hypertension Drug Thelin From Market

Law360, New York (December 10, 2010, 12:16 PM EST) -- Pfizer Inc. said Friday that it would withdraw its pulmonary arterial hypertension treatment Thelin from the marketplace and discontinue clinical studies of the drug, which has been at the center of securities class action litigation.

The decision was made in the interest of patient safety, based on a review of emerging safety information from clinical trials and post-marketing reports, the drug company said.

Liver toxicity was already a known complication of Thelin’s class of drugs, but Pfizer said that a new potentially life-threatening, idiosyncratic risk of...
To view the full article, register now.